Impact BioMedical, INC. Net Income
Impact BioMedical, INC. (IBO) reported Net Income of -$699.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-07
- Impact BioMedical, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$699.00K.
- Impact BioMedical, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$2.29M.
- Impact BioMedical, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $5.25M.
- Impact BioMedical, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$1.47M, a 134.61% decline year-over-year.
- Impact BioMedical, INC. net income (loss) attributable to parent for fiscal 2025 was -$11.84M.
- Impact BioMedical, INC. net income (loss) attributable to parent for fiscal 2024 was -$24.71M.
- Impact BioMedical, INC. net income (loss) attributable to parent for fiscal 2023 was -$4.34M.
- Impact BioMedical, INC. net income (loss) attributable to parent for fiscal 2022 was -$7.25M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$699.00K 10-Q · filed 2026-08-07 | -$2.98M 10-Q · filed 2026-08-07 | $2.26M derived: sum of 3 quarters · filed 2026-08-07 | $789.00K derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | -$2.29M 10-Q · filed 2026-05-12 | $2.96M derived: sum of 2 quarters · filed 2026-05-12 | $1.49M derived: sum of 3 quarters · filed 2026-05-12 | -$12.86M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.77M derived: sum of 2 quarters · filed 2026-03-11 | -$10.57M derived: sum of 3 quarters · filed 2026-08-07 | -$11.84M 10-K · filed 2026-03-11 | ||||
| 2025-09-30 | -$1.47M 10-Q · filed 2025-11-07 | -$15.82M derived: sum of 2 quarters · filed 2026-08-07 | -$17.08M 10-Q · filed 2025-11-07 | -$44.19M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | -$14.35M 10-Q · filed 2026-08-07 | -$15.61M 10-Q · filed 2026-08-07 | -$42.72M derived: sum of 3 quarters · filed 2026-08-07 | -$38.47M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | -$1.27M 10-Q · filed 2026-05-12 | -$28.38M derived: sum of 2 quarters · filed 2026-05-12 | -$24.13M derived: sum of 3 quarters · filed 2026-05-12 | -$25.02M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$27.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$22.86M derived: sum of 2 quarters · filed 2026-03-11 | -$23.75M derived: sum of 3 quarters · filed 2026-03-11 | -$24.71M 10-K · filed 2026-03-11 | ||||
| 2024-09-30 | $4.25M 10-Q · filed 2025-11-07 | $3.36M derived: sum of 2 quarters · filed 2025-11-07 | $2.40M 10-Q · filed 2025-11-07 | $2.36M 10-Q · filed 2024-11-12 | $1.21M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | -$889.00K 10-Q · filed 2025-08-14 | -$1.85M 10-Q · filed 2025-08-14 | -$1.88M 10-Q · filed 2024-08-13 | -$3.04M derived: sum of 3 quarters · filed 2025-08-14 | -$4.22M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$962.00K 10-Q · filed 2025-05-14 | -$998.00K 10-Q · filed 2024-05-10 | -$2.15M derived: sum of 2 quarters · filed 2025-05-14 | -$3.33M derived: sum of 3 quarters · filed 2025-05-14 | -$4.45M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$2.37M derived: sum of 2 quarters · filed 2025-03-28 | -$3.49M derived: sum of 3 quarters · filed 2025-03-28 | -$4.34M 10-K · filed 2025-03-28 | -$4.41M 10-K · filed 2024-02-20 | |||
| 2023-09-30 | -$1.18M 10-Q · filed 2023-11-13 | -$2.30M derived: sum of 2 quarters · filed 2023-11-13 | -$3.15M 10-Q · filed 2024-11-12 | -$6.51M derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2023-06-30 | -$1.12M 10-Q · filed 2023-10-05 | -$1.97M 10-Q · filed 2024-08-13 | -$5.34M derived: sum of 3 quarters · filed 2024-05-10 | -$7.57M derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2023-03-31 | -$849.00K 10-Q · filed 2024-05-10 | -$4.21M derived: sum of 2 quarters · filed 2024-05-10 | -$6.45M derived: sum of 3 quarters · filed 2024-05-10 | -$7.25M derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2022-12-31 | -$3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$5.60M derived: sum of 2 quarters · filed 2024-02-20 | -$6.40M derived: sum of 3 quarters · filed 2024-02-20 | -$7.25M 10-K · filed 2024-02-20 | ||||
| 2022-09-30 | -$2.24M 10-Q · filed 2023-11-13 | -$3.04M derived: sum of 2 quarters · filed 2023-11-13 | -$3.89M 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | -$799.00K 10-Q · filed 2023-10-05 | -$1.54M 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |